Radius Health, Inc. (NASDAQ:RDUS) – Investment analysts at Cantor Fitzgerald decreased their FY2017 EPS estimates for shares of Radius Health in a report issued on Tuesday. Cantor Fitzgerald analyst M. Goldstein now anticipates that the biopharmaceutical company will earn ($4.70) per share for the year, down from their previous forecast of ($4.36). Cantor Fitzgerald currently has a “Buy” rating and a $58.00 target price on the stock. Cantor Fitzgerald also issued estimates for Radius Health’s FY2018 earnings at ($3.47) EPS.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by $0.23. The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same period in the previous year, the business posted ($1.01) earnings per share.
COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Weighs in on Radius Health, Inc.’s FY2017 Earnings (RDUS)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2796629/cantor-fitzgerald-weighs-in-on-radius-health-inc-s-fy2017-earnings-rdus.html.
Other research analysts have also recently issued research reports about the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a report on Friday, April 28th. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Radius Health in a report on Monday, May 15th. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Jefferies Group LLC set a $34.00 price target on shares of Radius Health and gave the stock a “hold” rating in a report on Monday, June 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. Radius Health presently has a consensus rating of “Hold” and a consensus target price of $53.60.
Shares of Radius Health (RDUS) opened at 34.98 on Thursday. Radius Health has a 52-week low of $31.58 and a 52-week high of $59.88. The firm has a 50-day moving average of $44.04 and a 200-day moving average of $40.46. The company’s market cap is $1.52 billion.
In other Radius Health news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the business’s stock in a transaction dated Thursday, May 18th. The shares were purchased at an average price of $34.41 per share, for a total transaction of $1,720,500.00. Following the completion of the purchase, the insider now directly owns 4,958,799 shares of the company’s stock, valued at $170,632,273.59. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 40,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was acquired at an average price of $36.25 per share, for a total transaction of $1,450,000.00. Following the purchase, the insider now directly owns 4,998,799 shares of the company’s stock, valued at $181,206,463.75. The disclosure for this purchase can be found here. Insiders bought 180,000 shares of company stock worth $6,219,300 in the last quarter. Company insiders own 15.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in RDUS. BlackRock Inc. raised its stake in Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after buying an additional 2,628,070 shares during the last quarter. Norges Bank acquired a new stake in Radius Health during the fourth quarter worth $13,519,000. Credit Agricole S A acquired a new stake in Radius Health during the first quarter worth $10,026,000. BB Biotech AG raised its stake in Radius Health by 4.1% in the first quarter. BB Biotech AG now owns 4,540,399 shares of the biopharmaceutical company’s stock worth $175,486,000 after buying an additional 180,000 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Radius Health by 67.8% in the first quarter. Bank of New York Mellon Corp now owns 444,049 shares of the biopharmaceutical company’s stock worth $17,163,000 after buying an additional 179,471 shares during the last quarter.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.